The Pharmacology of the Cannabinoid System—A Question of Efficacy and Selectivity

被引:0
|
作者
Christopher J. Fowler
机构
[1] Umeå University,Department of Pharmacology and Clinical Neuroscience
来源
Molecular Neurobiology | 2007年 / 36卷
关键词
Cannabinoid receptor; Anandamide; 2-Arachidonoylglycerol; Fatty acid amide hydrolase; Monoacylglycerol lipase; Non-steroidal anti-inflammatory drugs;
D O I
暂无
中图分类号
学科分类号
摘要
Our knowledge of the function of the cannabinoid system in the body has been aided by the availability of pharmacological agents that affect its function. This has been achieved by the design of agents that either directly interact with the receptor (agonists and antagonist/inverse agonists) and agents that indirectly modulate the receptor output by changing the levels of the endogenous cannabinoids (endocannabinoids). In this review, examples of the most commonly used receptor agonists, antagonists/inverse agonists, and indirectly acting agents (anandamide uptake inhibitors, fatty acid amide hydrolase inhibitors, monoacylglycerol lipase inhibitors) are given, with particular focus upon their selectivity and, in the case of the directly acting compounds, efficacy. Finally, the links between the endocannabinoid and cyclooxygenase pathways are explored, in particular, with respect to agents whose primary function is to inhibit cyclooxygenase activity, but which also interact with the endocannabinoid system.
引用
收藏
页码:15 / 25
页数:10
相关论文
共 50 条
  • [21] Cannabinoid pharmacology and therapy in gut disorders
    Uranga, J. A.
    Vera, G.
    Abalo, R.
    BIOCHEMICAL PHARMACOLOGY, 2018, 157 : 134 - 147
  • [22] The pharmacology of cannabinoid receptors and their ligands: an overview
    R G Pertwee
    International Journal of Obesity, 2006, 30 : S13 - S18
  • [23] Evaluating the efficacy of - A terrorism question/answer system
    Schumaker, Robert P.
    Liu, Ying
    Ginsburg, Mark
    Chen, Hsinchun
    COMMUNICATIONS OF THE ACM, 2007, 50 (07) : 74 - 80
  • [24] Pharmacology of antidepressants: Selectivity or multiplicity?
    Westenberg, HGM
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 4 - 8
  • [25] Exploiting modern cannabinoid pharmacology for therapeutic gain?
    Ritter, James M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (05) : 671 - 673
  • [26] Pharmacology and Toxicology of the Synthetic Cannabinoid Receptor Agonists
    Lovett, C.
    Wood, D. M.
    Dargan, P. I.
    REANIMATION, 2015, 24 (05): : 527 - 541
  • [27] Cannabinoid physiology and pharmacology: 30 years of progress
    Howlett, AC
    Breivogel, CS
    Childers, SR
    Deadwyler, SA
    Hampson, RE
    Porrino, LJ
    NEUROPHARMACOLOGY, 2004, 47 : 345 - 358
  • [28] Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous Cannabinoid
    Hillard, CJ
    Campbell, WB
    JOURNAL OF LIPID RESEARCH, 1997, 38 (12) : 2383 - 2398
  • [29] Problems of drug selectivity and dose - pharmacology
    Ramage, A
    JOURNAL OF PHYSIOLOGY-LONDON, 2005, 569 (02): : 711 - 711